Final Program

WEDNESDAY • MAY 18 361
P29
P30
P31
P32
P33
P34
P35
P36
P37
P38
P39
Efficacy and Safety of Indacaterol/Glycopyrrolate Versus Its
Monocomponents and Placebo in Symptomatic Patients
(GOLD B and GOLD D) with COPD: FLIGHT1/FLIGHT2 Pooled
Analysis in the US Subgroup/T. Ayers, S. Maitra, M. Larbig, D.
Banerji, East Hanover, NJ, p.A6799
Indacaterol/Glycopyrrolate Improves Lung Function, Dyspnea
and Health Status in Symptomatic Patients with COPD Using
Prior LAMA, LABA or LABA/ICS: Post-Hoc Analysis from
Pooled FLIGHT1 and FLIGHT2 Studies/T. Ayers, S. Maitra, R.
Fogel, D. Banerji, East Hanover, NJ, p.A6800
Indacaterol/Glycopyrrolate Significantly Improves COPD
Assessment Test (CAT) Scores in US Patients with
Moderate-to-Severe COPD: Subgroup Analysis from Pooled
FLIGHT1 and FLIGHT2 Studies/R. Fogel, S. Maitra, F. Patalano,
D. Banerji, East Hanover, NJ, p.A6801
Impact of a Long-Acting Beta Agonist and an Inhaled
Corticosteroid in COPD Patients with Moderate Airflow
Obstruction and CV Disease or Risk: A Factorial Analysis of
the SUMMIT Trial/P.M.A. Calverley, J.A. Anderson, R.D. Brook, C.
Crim, S. Kilbride, F.J. Martinez, D.E. Newby, J. Vestbo, J.C. Yates,
B. Celli, Liverpool, United Kingdom, p.A6802
Using Different Sets of Patient-Relevant Outcomes in Chronic
Obstructive Pulmonary Disease to Evaluate Efficacy of
Tiotropium Respimatr - a Post-Hoc Analysis/R. Dahl, A.
Anzueto, N. Metzdorf, A. Mueller, P.M. Calverley, Odense C.,
Denmark, p.A6803
Efficacy and Safety of Tiotropium + Olodaterol in Patients with
COPD by ATS Category/F. Maltais, E. Pizzichini, L. Gronke, F.
Vob, E. Derom, Quebec, Canada, p.A6804
Effect of Tiotropium + Olodaterol Therapy on COPD
Exacerbations in the TONADOr Studies/E. Derom, M. Flezar, L.
Gronke, F. Vob, R. Buhl, Ghent, Belgium, p.A6805
Tiotropium + Olodaterol Therapy Provides Lung-Function
Benefits Over Salmeterol + Fluticasone Propionate Irrespective
of Prior ICS Treatment: Post Hoc Analyses of the ENERGITOr
Study/E. Derom, E. Clerisme-Beaty, L. Gronke, F. Voss, D. Zhai, L.
Bjermer, Gent, Belgium, p.A6806
Analysis of Rescue Medication Use Over 1 Year in Patients
Receiving LAMA, LABA, or Combination Maintenance
Treatment for COPD in the TONADOr Studies/C.B. Cooper, R.
Abrahams, G.T. Ferguson, E. Clerisme-Beaty, F. Vob, R. Buhl, Los
Angeles, CA, p.A6807
Lung-Function Response to Tiotropium + Olodaterol in
Patients with COPD with b-Agonist Reversibility/D.P. Tashkin,
G.T. Ferguson, E. Clerisme-Beaty, F. Vob, R. Buhl, Los Angeles,
CA, p.A6808
Tiotropium + Olodaterol Therapy Provides Symptomatic
Benefits Irrespective of Prior Maintenance Treatment: Post
Hoc Analyses of the OTEMTOr Studies/R. Abrahams, G.T.
Ferguson, L. Bjermer, L. Gronke, F. Vob, D. Singh, Morgantown,
WV, p.A6809
P40
Facilitator:
P41
P42
P43
P44
P45
P46
P47
P48
P49
P50
P51
Treatment with Tiotropium Plus Olodaterol Respimat Improves
Physical Functioning of COPD Patients in a Real Life
Setting/M. Haensel, T. Glaab, R. Sauer, R. Rubin, R. Buhl,
Ingelheim am Rhein, Germany, p.A6810
C.B. Cooper, MD, Los Angeles, CA
Inhaler Errors After Reading the Patient Information Leaflet in
Patients with COPD: A Comparison of Elliptar with Five Inhaler
Devices/J. Van Der Palen, M. Thomas, H. Chrystyn, R. Sharma, V.
Imber, C.-Q. Zhu, N. Barnes, Enschede, Netherlands, p.A6811
Training and Time to Achieve Correct Inhaler Use: A
Comparison Between Inhalers in Patients with COPD/J. Van
Der Palen, M. Thomas, H. Chrystyn, R. Sharma, V. Imber, C.-Q.
Zhu, H. Svedsater, Enschede, Netherlands, p.A6812
Inhaler Preference in Patients with COPD: A Comparison of
Elliptar with Five Inhaler Devices/J. Van Der Palen, M. Thomas,
H. Chrystyn, R. Sharma, H. Svedsater, C.-Q. Zhu, N. Barnes,
Enschede, Netherlands, p.A6813
Benefits of Tiotropium Versus Placebo for Delaying Clinically
Significant Events in Patients with Moderate COPD (GOLD
2)/K. Rabe, N. Metzdorf, F. Vob, C. Hallmann, L. Gronke, D.
Tashkin, Grosshansdorf, Germany, p.A6814
Comparative Efficacy of Umeclidinium Versus Other
Long-Acting Muscarinic Antagonist in Combination with
ICS/LABA/V. Chounta, E. Huisman, A.S. Ismaila, A. Karabis, Y.S.
Punekar, Brentford, United Kingdom, p.A6815
Treatment Satisfaction and Preference with
Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy
in Comparison to Tiotropium Monotherapy - Results of the
FAVOR Study/P. Kardos, I. Hagedorn, Frankfurt, Germany,
p.A6816
Improvement in Lung Function and Symptom Control with
Aclidinium Bromide Versus Tiotropium and Placebo in
Symptomatic Patients with COPD: Post-Hoc Analysis of a
Phase IIIb Study/J. Beier, R. Mroz, A.-M. Kirsten, F. Chuecos, E.
Garcia Gil, Wiesbaden, Germany, p.A6817
Improvement in Symptom Severity and Quality of Life in
Patients with COPD Treated with Aclidinium Bromide: Results
of a Non-Interventional Study/J. Beier, T. Plate, A. Prechtl,
Wiesbaden, Germany, p.A6818
Risk of Pneumonia with Budesonide-Containing Treatments in
COPD: An Individual Patient-Level Pooled Analysis of
Interventional Studies/C. Jorup, S. Hollis, D. Lythgoe, G.
Martensson, P. Regnell, G. Eckerwall, Molndal, Sweden, p.A6819
The Effect of Aclidinium Bromide 400 µg on Lung Function,
Sleep Quality and Physical Activity in Patients with Chronic
Obstructive Pulmonary Disease: Results of a Phase IV Pilot
Study/H. Magnussen, M. Arzt, S. Andreas, T. Plate, A. Ribera, B.
Seoane, H. Watz, A.-M. Kirsten, Grosshansdorf, Germany, p.A6820
Should Inhaled Corticosteroids Be Considered in Group A and
B COPD Patients with Marked Post-Bronchodilator
Reversibility of FEV1/J. Balachandran, 691009, India, p.A6821
WEDNESDAY MORNING
ATS 2016 • San Francisco